AR Highlights Template
FINANCIAL INDICATORS
Our key performance indicators (KPIs)
2021 was a year of strong growth for Ipsen. Our key performance indicators (KPIs) are testament to the power of our strategy. By focusing our expertise in oncology, rare disease and neuroscience, we are advancing medicine and improving patients’ lives.
Core operating income sales
€2869.9 M
Total sales 2021
+12.3 % YOY
€2476.2 M
Record core
operating margin
€2983.1 M
Consumer HC Sales
+8.1% YOY
€2576.2 M
Oncology Sales
+10.8 % YOY
R&D investment
€388.8 M
Total sales 2021
+12.3 % YOY
€405.6 M
Record core
operating margin
€428.4 M
Consumer HC Sales
+8.1% YOY
Key facts
We want to broaden and deepen our expertise as well as fully leverage the collective intelligence of the company. We are accelerating our efforts to truly embrace diversity in all our facets and make Ipsen a more inclusive organization.
Total sales CAGR between +4% and +6%
The total sales CAGR between +4% and +6% from 2021 to 2024
Commitment to invest in the R&D
The commitment to investment in the R&D i supported by SG&A effciencies
€3.5 BN for invest by 2024
Cumulative remaining firepower for investment by 2024**
Ownership of Ipsen’s share capital (% of total capital)
Footnotes
* France, Germany, Italy, Spain and the United Kingdom
** Including the divestment of the CHC business
*** Directly and indirectly through its subsidiary MR BMH
AR Footprint Template
AR Patients & Society Template
AR Together Template
AR Focus Template
AR Value Creation Template
AR Interview of David Template